The following therapeutic options are recommended as second-line therapy for pediatric patients with NF1 and the presence of recurrent or refractory optic pathway gliomas: vinblastine, carboplatin, vinorelbine, or bevacizumab, isolated or in combination. The gene discussed is NF1; the disease is optic pathway glioma.